Key Takeaways
- • The University of Utah and EPIC Ventures launched University of Utah Ventures, Powered by EPIC, a new early-stage venture capital fund with $200 million in fresh capital targeting software, healthcare, life sciences, and fintech sectors across the region.
- • The partnership leverages the University of Utah's ~$700 million annual research funding and track record of successful alumni founders alongside EPIC Ventures' operational expertise and scaling capabilities in early-stage companies.
- • The U and EPIC previously collaborated on Recursion Pharmaceuticals, which has grown into a $2 billion publicly traded company, demonstrating the partnership's ability to identify and develop commercially viable deep-tech ventures.
- • The fund is integrated into the University of Utah's broader Vice President of Research strategic plan to accelerate technology transfer and embed commercialization earlier in the research discovery pipeline, addressing a critical gap in academic innovation ecosystems.
- • The Utah Venture Hub, the university's designated startup office under associate vice president Jim Hotaling, facilitated the partnership and will manage ongoing collaboration and portfolio company support.
Summary
The University of Utah and Salt Lake City-based EPIC Ventures announced a strategic partnership to establish University of Utah Ventures, Powered by EPIC, a new early-stage venture capital fund capitalized with $200 million. The initiative combines the university's substantial research infrastructure and entrepreneurial talent with EPIC Ventures' operational expertise and network to accelerate technology commercialization across multiple sectors including software, healthcare, life sciences, and financial technology.
University of Utah President Taylor Randall characterized the partnership as "transformative," emphasizing its dual mandate to drive innovation within the institution while catalyzing regional economic growth. The fund is positioned to address a critical market inefficiency: translating academic research into commercially viable companies. With the university generating approximately $700 million in annual research funding and a demonstrated history of successful founder alumni, the partnership provides EPIC Ventures with proprietary deal flow while offering academic researchers a clear pathway to venture-scale capital and operational support.
The partnership's track record is substantive. EPIC Ventures and the University of Utah previously invested in and supported Recursion Pharmaceuticals, which has since grown into a publicly traded company valued at $2 billion—demonstrating the institutional ability to identify and develop transformational early-stage ventures. According to Erin Rothwell, vice president of research at the university, the venture fund represents a strategic expansion of the institution's commercialization capabilities, integrating venture-stage investments and expertise earlier into the research discovery pipeline rather than as a downstream activity.
The Utah Venture Hub, the university's dedicated startup office led by associate vice president Jim Hotaling, facilitated the partnership formation and will serve as the operational hub for deal sourcing, portfolio company support, and ongoing collaboration between institutional researchers and EPIC's venture team. This structural integration positions the fund to function as both a capital provider and a bridge between academic innovation and market-ready commercialization. The partnership reflects a broader institutional trend among research universities to directly participate in venture capital returns while accelerating technology transfer to regional and national markets.
University of Utah President Taylor Randall characterized the partnership as "transformative," emphasizing its dual mandate to drive innovation within the institution while catalyzing regional economic growth. The fund is positioned to address a critical market inefficiency: translating academic research into commercially viable companies. With the university generating approximately $700 million in annual research funding and a demonstrated history of successful founder alumni, the partnership provides EPIC Ventures with proprietary deal flow while offering academic researchers a clear pathway to venture-scale capital and operational support.
The partnership's track record is substantive. EPIC Ventures and the University of Utah previously invested in and supported Recursion Pharmaceuticals, which has since grown into a publicly traded company valued at $2 billion—demonstrating the institutional ability to identify and develop transformational early-stage ventures. According to Erin Rothwell, vice president of research at the university, the venture fund represents a strategic expansion of the institution's commercialization capabilities, integrating venture-stage investments and expertise earlier into the research discovery pipeline rather than as a downstream activity.
The Utah Venture Hub, the university's dedicated startup office led by associate vice president Jim Hotaling, facilitated the partnership formation and will serve as the operational hub for deal sourcing, portfolio company support, and ongoing collaboration between institutional researchers and EPIC's venture team. This structural integration positions the fund to function as both a capital provider and a bridge between academic innovation and market-ready commercialization. The partnership reflects a broader institutional trend among research universities to directly participate in venture capital returns while accelerating technology transfer to regional and national markets.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.